Organon Overview

  • Year Founded
  • 1923

Year Founded

  • Status
  • Public

  • Employees
  • 10,000

Employees

  • Stock Symbol
  • OGN

Stock Symbol

  • Investments
  • 12

  • Share Price
  • $13.89
  • (As of Friday Closing)

Organon General Information

Description

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Contact Information

Website
www.organon.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 30 Hudson Street
  • Jersey City, NJ 07302
  • United States
+1 (551)
Primary Industry
Pharmaceuticals
Other Industries
Other Devices and Supplies
Drug Discovery
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • 30 Hudson Street
  • Jersey City, NJ 07302
  • United States
+1 (551)

Organon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Organon Stock Performance

As of 20-Nov-2026, Organon’s stock price is $13.89. Its current market cap is $3.65B with 263M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.89 $13.91 $5.69 - $13.94 $3.65B 263M 2.73M $0.81

Organon Financials Summary

As of 30-Sep-2026, Organon has a trailing 12-month revenue of $6.1B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 11,018,749 10,020,077 11,828,480 11,925,845
Revenue 6,099,000 6,216,000 6,403,000 6,263,000
EBITDA 1,293,000 1,290,000 1,604,000 1,436,000
Net Income 213,000 187,000 864,000 1,023,000
Total Assets 13,401,000 12,867,000 13,101,000 12,058,000
Total Debt 8,554,000 8,644,000 8,880,000 8,760,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Organon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Organon‘s full profile, request access.

Request a free trial

Organon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthi
Pharmaceuticals
Jersey City, NJ
10,000 As of 2025

Rahway, NJ
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Organon Competitors (3)

One of Organon’s 3 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
Pfizer Corporation New York, NY
Sanofi Corporation Gentilly, France
You’re viewing 3 of 3 competitors. Get the full list »

Organon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Organon Investments & Acquisitions (12)

Organon’s most recent deal was a Accelerator/Incubator with Elle, MD Biotechnologies. The deal was made on 09-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Elle, MD Biotechnologies 09-Jun-2026 Accelerator/Incubator Other Devices and Supplies
Myri Health 06-May-2026 Accelerator/Incubator Other Healthcare Technology Systems
Merck Sharp Dohme Pharma (Oss Bio-Tech Manufacturing Facility Located in Netherlands) 01-Jul-2025 Corporate Asset Purchase Buildings and Property
Sympa Health 01-Jan-2025 Accelerator/Incubator Other Healthcare Technology Systems
InBalance 03-Nov-2024 Accelerator/Incubator Other Healthcare Technology Systems
You’re viewing 5 of 12 investments and acquisitions. Get the full list »

Organon ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

25.6 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Organon’s complete esg history, request access »

Organon Exits (1)

Organon’s most recent exit was on 16-Jun-2021 from Jada System. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Jada System 16-Jun-2021 Completed
To view Organon’s complete exits history, request access »

Organon Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Dermavant Sciences Long Beach, CA 2016

Organon FAQs

  • When was Organon founded?

    Organon was founded in 1923.

  • Where is Organon headquartered?

    Organon is headquartered in Jersey City, NJ.

  • What is the size of Organon?

    Organon has 10,000 total employees.

  • What industry is Organon in?

    Organon’s primary industry is Pharmaceuticals.

  • Is Organon a private or public company?

    Organon is a Public company.

  • What is Organon’s stock symbol?

    The ticker symbol for Organon is OGN.

  • What is the current stock price of Organon?

    As of 20-Nov-2026 the stock price of Organon is $13.89.

  • What is the current market cap of Organon?

    The current market capitalization of Organon is $3.65B.

  • What is Organon’s current revenue?

    The trailing twelve month revenue for Organon is $6.1B.

  • Who are Organon’s competitors?

    Merck & Co., Pfizer, and Sanofi are competitors of Organon.

  • What is Organon’s annual earnings per share (EPS)?

    Organon’s EPS for 12 months was $0.81.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process